FDA Grants Accelerated Approval to Zanubrutinib for Mantle Cell Lymphoma
Nov 14
2019
The Food and Drug Administration granted accelerated approval to zanubrutinib (BRUKINSA, BeiGene, Ltd.) for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.